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Abstract
Background: The optimal approach to the drainage of malignant obstruction at the liver hilum remains
uncertain. We aim to compare percutaneous transhepatic biliary drainage (PTBD) to endoscopic retrograde
cholangiography (ERC) as the first intervention in patients with cholestasis due to suspected malignant hilar
obstruction (MHO).
Methods: The INTERCPT trial is a multi-center, comparative effectiveness, randomized, superiority trial of PTBD
vs. ERC for decompression of suspected MHO. One hundred and eighty-four eligible patients across medical
centers in the United States, who provide informed consent, will be randomly assigned in 1:1 fashion via a
web-based electronic randomization system to either ERC or PTBD as the initial drainage and, if indicated,
diagnostic procedure. All subsequent clinical interventions, including crossover to the alternative procedure,
will be dictated by treating physicians per usual clinical care. Enrolled subjects will be assessed for successful
biliary drainage (primary outcome measure), adequate tissue diagnosis, adverse events, the need for additional
procedures, hospitalizations, and oncological outcomes over a 6-month follow-up period. Subjects, treating
clinicians and outcome assessors will not be blinded.
Discussion: The INTERCPT trial is designed to determine whether PTBD or ERC is the better initial approach
when managing a patient with suspected MHO, a common clinical dilemma that has never been investigated
in a randomized trial.
Trial registration: ClinicalTrials.gov, Identifier: NCT03172832. Registered on 1 June 2017.
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Background
Both percutaneous transhepatic biliary drainage (PTBD)
and endoscopic retrograde cholangiography (ERC)
are accepted approaches in the management of pa-
tients with malignant obstruction at the liver hilum.
In routine clinical practice, ERC is generally favored
on the basis of: (1) high technical and clinical suc-
cess rates for other (non-hilar) indications; (2) the
perceived safety of ERC relative to PTBD; (3) the
perceived ability to perform more comprehensive tis-
sue sampling at the time of ERC compared to PTBD;
(4) the avoidance of external tubes which are often
needed for PTBD; and (5) because patients with sus-
pected malignant hilar obstruction (MHO) typically
present to, and are managed by, gastroenterologists.
However: (1) observational data suggest that PTBD
is superior for achieving complete drainage of MHO
[1–3] and some guidelines recommend the percutan-
eous approach over ERC for Bismuth type 3 and 4
hilar strictures [4]; (2) the generally quoted risks of
PTBD are based on outdated studies and may be
exaggerated [5]; and (3) endoscopic diagnosis of
indeterminate biliary strictures remains suboptimal
despite the use of cholangioscopy and multi-modal
sampling.
Although existing evidence suggests that many pa-
tients who undergo initial ERC require subsequent
PTBD for adequate drainage [3, 6], no randomized
trials comparing the two modalities for suspected
MHO have been published. We hypothesize that
even though PTBD will be more effective than ERC
for decompression of suspected MHO, this advan-
tage will be offset by the favorable safety profile and
superior diagnostic capacity of ERC. If, however,
PTBD is found to be substantially superior in terms
of drainage, or if the potential advantages of ERC
are not realized, then the existing clinical approach
to MHO must be reappraised. Moreover, identifying
patient and stricture characteristics that predict re-
sponse to PTBD or ERC may be important for
informing clinical decision-making and guidelines.
Methods
Design
The INTerventional Radiology vs. ERC for Perihilar
Tumors (INTERCPT) trial is a multi-center, comparative
effectiveness, randomized, superiority trial of PTBD vs.
ERC for decompression of suspected MHO. Ethical ap-
proval has been obtained from the Institutional Review
Board at the primary site (Medical University of South
Carolina, Pro00063825) and several sub-sites. The
remaining sites will only enroll subjects once local regu-
latory approval has been obtained.
Patients
The eligibility criteria are listed in Table 1. Informed
consent will be obtained from all study participants. We
plan to enroll patients of 40 years of age or older with
cholestasis who have radiographic evidence of obstruc-
tion at the liver hilum. Thus, patients with a docu-
mented hilar stricture on magnetic resonance imaging
(MRI) or those with a dilated intrahepatic, but not extra-
hepatic biliary system, on ultrasound or computed tom-
ography scan (CT) will be eligible. To maximize
generalizability, this trial is intended to mimic routine
clinical practice as closely as possible, in which the deci-
sion to proceed with biliary decompression is often
based on information from one – but not all – of these
radiographic tests. Patients will be excluded if the hilum
is not directly involved, if there is reason to believe that
the stricture is benign (because these are typically better
managed endoscopically or surgically), or if there are
relative contraindications to PTBD or ERC that clearly
favor one procedure over the other.
Table 1 Eligibility criteria
Inclusion criteria
1. Age ≥ 40 years (to reduce the likelihood of enrolling patients with
obstruction due to primary sclerosing cholangitis)
2. Cholestatic liver function tests, including serum alkaline
phosphatase level ≥ 300 IU/L and bilirubin level ≥ 3.7 mg/dL
3. Radiographic evidence of a biliary hilar stricture or intrahepatic but
no extrahepatic biliary ductal dilation
Exclusion criteria
1. Known radiographic evidence of a Bismuth-Corlette type 1 biliary
stricture
2. Known diagnosis of primary sclerosing cholangitis without
suspicion of dominant hilar stricture
3. Recent cholecystectomy, liver resection, or biliary surgery within
12 months
4. Known Mirizzi syndrome
5. Known IgG4-mediated cholangiopathy
6. Significant liver metastatic disease interfering with safe/effective
PTBD
7. Significant ascites interfering with safe/effective PTBD
8. Known regional malignant-appearing adenopathy or extrabiliary
mass, indicating the need for concurrent EUS-FNA
9. Prior ERC or PTBD for hilar obstruction
10. Surgically altered luminal anatomy other than prior Billroth
reconstruction
11. Standard general contraindications to ERC or PTBD (e.g.,
hemodynamic instability, uncorrected coagulopathy, etc.)
12. Pregnancy
13. Inability or unwillingness to follow study protocol
ERC, endoscopic retrograde cholangiography, EUS-FNA, endoscopic ultrasound-
guided fine-needle aspiration biopsy, PTBD percutaneous transhepatic
biliary drainage
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Setting
Patients will be identified and enrolled at approximately
25 tertiary medical centers across the United States, the
exact setting in which such patients are managed in rou-
tine clinical practice and the decision of PTBD vs. ERC
made because their high complexity generally prompts
referral to a tertiary center. Non-referral hospitals were
not included in the network because MHO patients re-
quire not only tertiary and quaternary procedural care
(to include interventions like cholangioscopy, intraductal
photodynamic therapy, and radiofrequency ablation), but
also National Cancer Institute (NCI)-designated cancer
center-type expertise in medical and surgical oncology
as part of a multi-disciplinary Tumor Board approach.
Randomization
Eligible patients who provide informed consent will be ran-
domly assigned in 1:1 fashion to PTBD or ERC as the first
intervention using a web-based, electronic randomization
system. The randomization schedule will be generated cen-
trally at the data coordinating center and will ensure treat-
ment balance within site. The study allocation, interventions,
and assessments as adapted from the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
Figure, are outlined in Fig. 1; Additional files 1 and 2.
Procedure
Enrolled subjects will undergo PTBD or ERC according to
study group assignment. All components of the procedure
and related interventions will be dictated by treating
physicians per usual care. Specifically, the technical ap-
proach to drainage (e.g., bilateral vs. unilateral, functional
lobe only) and tissue sampling (e.g. brushing, intraductal bi-
opsies, cholangioscopy, fluorescence in situ hybridization,
etc.) will be determined by the treating physicians and pro-
ceduralists performing the PTBD or ERC.
Blinding
Given the substantial differences in approach between
PTBD and ERC, including pre-procedure instructions
and consent, post-procedure observation and follow-up,
location within a hospital, as well as the need for a per-
cutaneous catheter after PTBD, blinding subjects to
study intervention is not possible. Similarly, there is no
practical method to ensure masking of treating clinicians
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Fig. 1 Enrollment, intervention, and assessments in the INTERCPT trial
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and outcome assessors who will be reviewing medical
records.
Follow-up
All follow-up decisions pertaining to the need for re-
peat procedures to address inadequate drainage or
incomplete tissue sampling, or the decision to refer
the patient for the alternative procedure will be dic-
tated by treating physicians. All enrolled subjects
will be followed for 6 months after the index (ran-
domly assigned) procedure, primarily through review
of their medical records.
Outcomes
The primary endpoint of successful biliary drainage will
be defined as a 50% reduction in bilirubin level within 3
weeks of the study intervention without additional ERC
or PTBD during that timeframe.
Secondary endpoints will include:
1. An alternative definition of successful biliary
drainage, defined as improvement in the serum
bilirubin level to ≤ 2.5 mg/dL as a result of the index
(randomization) intervention without the need for
additional PTBD or ERC. This bilirubin level is
considered informative because it is the threshold
most commonly used by oncologists to administer
chemotherapy
2. Adverse events related to PTBD and ERC, defined
according to standard consensus guideline
documents published in the interventional radiology
[5] and gastroenterology [7] literature, respectively
3. Malignant tissue diagnosis, defined as a definitive
diagnosis of malignancy documented in the
subject’s medical record. We recognize that a
fraction of patients will not have malignant
obstruction, will not require a tissue diagnosis
(known alternative primary cancer), or that a
“gold standard” diagnostic test may not be
available within the follow-up period in patients
who are not diagnosed with cancer. We do,
however, expect that patients with cancer in
whom a tissue diagnosis is needed and possible
will be allocated evenly between study groups
4. Total number of procedures, hospitalizations, and
cancer-specific treatments during the 6-month
follow-up period
Statistical considerations
Given patient preference to avoid extracorporeal tubes as
well as the other perceived advantages of ERC, we estimate
that PTBD would have to be at least 20% more effective in
achieving successful biliary drainage to change clinical prac-
tice. Assuming that PTBD will be 90% effective in achieving
successful biliary decompression, we estimate that 160 pa-
tients (80 per study group) would provide a power of at
least 85% to detect a 20% absolute difference between study
groups on the basis of Fisher’s exact test, with a two-sided
significance level of 0.05. To address potential losses to
follow-up, the sample size is inflated by 15%. Thus, a total
of 184 subjects will be enrolled.
For analysis of the primary endpoint, we will use a chi-
square test to compare the proportion of patients
achieving a 50% reduction from baseline in serum biliru-
bin level within 3 weeks in the PTBD and ERC groups
using the intention-to-treat (ITT) principle. All random-
ized subjects will comprise the ITT population. A
secondary analysis will explore the potential variability
by study site and baseline serum bilirubin on the
primary outcome measure. Center differences will be
examined by including study site as a covariate in a
mixed-effects logistic regression model. Since there will
be roughly 25 centers with variable sample sizes, study
site will be modeled as a random effect. In addition to
the defined ITT analysis sample, a per-protocol sample
will be defined as a subset of the ITT sample. This
sample will be used for secondary sensitivity analyses of
the primary and secondary outcomes. The per-protocol
sample will include all randomized subjects that do not
have the following protocol deviations: eligibility viola-
tion, non-adherence to the randomized treatment, or
missing primary outcome. The secondary endpoints will
be compared between treatment arms using a chi-square
test or t test for independent means, as appropriate. There
will be no adjustment for multiple comparisons in the
pre-specified secondary analyses – including any patient-
centered outcomes defined in the planning phase – but all
additional exploratory analysis results will be interpreted
more conservatively using a significance level of 0.01
Recognizing that the study population may be het-
erogeneous in ways which could differentially impact
the success of ERC vs. PTC, we plan on performing
pre-defined exploratory analyses of treatment differ-
ences in the primary outcome, adjusting for possible
prognostic variables including: (1) age, (2) Body
Mass Index (BMI), (3) Charlson Comorbidity Index,
(4) presence of proven malignancy, (5) stricture of
Bismuth type, (6) presence of significant unilateral
lobar atrophy, and (7) recruitment at a center enrol-
ling an average of at least four patients/year. Each
covariate will be evaluated individually first in a lo-
gistic regression model that includes an interaction
effect with the treatment. Interactions will be exam-
ined at significance level of 0.15, though the trial
may be underpowered to assess such interactions. If
significant interaction (statistical and clinical) is con-
cluded, subgroup analyses may be considered. A
multi-variable model that includes covariates that
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contributed significantly as treatment modifiers indi-
vidually may then be constructed.
Discussion
The INTERCPT trial will be the only randomized com-
parison of PTBD vs. ERC as the initial intervention for
patients with suspected malignant hilar obstruction. This
is a fundamental question in clinical practice that has
remained unanswered because of the practical and
methodological complexities of such a trial.
To maximize practicality and generalizability, we have
adopted a pragmatic study design that includes only one
protocol-driven intervention – randomization to PTBD
or ERC. All other clinical decisions are deferred to treat-
ing physicians as clinically appropriate. We believe that
this experimental question is particularly suited for such
a pragmatically designed trial because the varying ap-
proaches to managing this highly complex disease
process between patients and across practice settings
constrains protocol standardization and threatens the
generalizability of a more traditional randomized con-
trolled trial (RCT) design. Standardizing procedural ap-
proach, re-interventions, and medication administration,
for example, would not only be impossible to ensure,
but would also critically limit external validity because of
the tremendous complexity in decision-making and the
extreme variability in approaches between providers and
institutions.
We appreciate that physicians may select ERC vs.
PTBD based on stricture characteristics and other con-
siderations such as the patient’s overall health and goals
of care. However, in many practice settings, ERC is typ-
ically attempted first because of its perceived advantages.
Moreover, stricture characteristics are often unknown
beforehand because routine MRI/ magnetic resonance
cholangiopancreatography (MRCP) has not been ob-
tained. Fundamentally, the goal of our study is to deter-
mine, at the point of care, whether ERC or PTBD is
preferable as the initial treatment of patients with
suspected MHO, even though stricture characteristics,
resectability status, and a definitive diagnosis may not be
known – the exact scenario often faced in real-world
clinical practice. Furthermore, this study may determine
whether a strategy of routine “planning” MRI/MRCP in
these cases to guide procedural selection improves
clinical outcomes.
We recognize that patients with suspected MHO are
often initially managed by gastroenterologists who may
be biased in favor of ERC and may prematurely re-divert
patients assigned to the PTBD group back to ERC, redu-
cing the likelihood of successful drainage via PTBD.
However, this potential bias will be mitigated by the fact
that suspected MHO patients are generally managed in
multi-disciplinary fashion by a Tumor Board, minimizing
the influence of any single provider on the care of a pa-
tient. We also recognize that ERC is well established in
the United States and Europe as the initial management
option for MHO, and thus it is possible that the results
of this study would not impact clinic practice. However,
we have selected a large enough effect size such that a
demonstrated superiority of PTBD would have to be
strongly considered in clinical decision-making and
guidelines.
The INTERCPT trial will be the first to determine
whether PTBD or ERC is the better initial intervention
for a patient with suspected MHO, or whether the treat-
ment approach should be individualized based on stric-
ture characteristics or other factors.
Trial status
This RCT began enrolling patients in October of 2017.
Additional files
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
Additional file 2: CONSORT 2010 Checklist of information to include
when reporting a randomised trial. (DOC 216 kb)
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